(Q37754925)

22 August 2017

title

Erlotinib: an EGF receptor tyrosine kinase inhibitor in non-small-cell lung cancer treatment (English)

1 reference

22 August 2017

1 reference

4

Fortunato Ciardiello

1 reference

22 August 2017

Clorinda Schettino

1

1 reference

22 August 2017

Maria Anna Bareschino

series ordinal

2

1 reference

22 August 2017

Vincenzo Ricci

series ordinal

3

1 reference

22 August 2017

publication date

1 April 2008

1 reference

Expert Review of Respiratory Medicine

22 August 2017

published in

1 reference

22 August 2017

volume

2

1 reference

22 August 2017

issue

2

1 reference

22 August 2017

page(s)

167-178

1 reference

Estimating the world cancer burden: Globocan 2000.

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

21 January 2018

Hypofractionation redux?

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Practical management of patients with non-small-cell lung cancer treated with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17476348.2.2.167

21 January 2018

Identifiers

DOI

10.1586/17476348.2.2.167

1 reference

22 August 2017

1 reference